CN112839654A - 制备取代的含吡啶酮的三环化合物的方法 - Google Patents

制备取代的含吡啶酮的三环化合物的方法 Download PDF

Info

Publication number
CN112839654A
CN112839654A CN201980037491.8A CN201980037491A CN112839654A CN 112839654 A CN112839654 A CN 112839654A CN 201980037491 A CN201980037491 A CN 201980037491A CN 112839654 A CN112839654 A CN 112839654A
Authority
CN
China
Prior art keywords
methoxy
methoxypropoxy
salt
molar ratio
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980037491.8A
Other languages
English (en)
Chinese (zh)
Inventor
陈帅
B·D·多尔西
D·B·哥彻夫
D·阮
M·K·帕勒拉
G·R·帕穆拉帕蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arbutus Biopharma Corp
Original Assignee
Arbutus Biopharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arbutus Biopharma Corp filed Critical Arbutus Biopharma Corp
Publication of CN112839654A publication Critical patent/CN112839654A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B49/00—Grignard reactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B51/00—Introduction of protecting groups or activating groups, not provided for in the preceding groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CN201980037491.8A 2018-04-12 2019-04-11 制备取代的含吡啶酮的三环化合物的方法 Pending CN112839654A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862656605P 2018-04-12 2018-04-12
US62/656,605 2018-04-12
US201862700048P 2018-07-18 2018-07-18
US62/700,048 2018-07-18
PCT/US2019/027004 WO2019200109A1 (en) 2018-04-12 2019-04-11 Methods for preparing substituted pyridinone-containing tricyclic compounds

Publications (1)

Publication Number Publication Date
CN112839654A true CN112839654A (zh) 2021-05-25

Family

ID=68163316

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980037491.8A Pending CN112839654A (zh) 2018-04-12 2019-04-11 制备取代的含吡啶酮的三环化合物的方法

Country Status (9)

Country Link
US (1) US11505551B2 (enExample)
EP (1) EP3773584A4 (enExample)
JP (1) JP2021521154A (enExample)
KR (1) KR20200142529A (enExample)
CN (1) CN112839654A (enExample)
AU (1) AU2019252441A1 (enExample)
CA (1) CA3096687A1 (enExample)
TW (1) TW202010499A (enExample)
WO (1) WO2019200109A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12128044B2 (en) 2018-08-28 2024-10-29 Sunshine Lake Pharma Co., Ltd. Fused tricyclic compounds and uses thereof in medicine
JP2022511378A (ja) 2018-09-30 2022-01-31 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 縮合四環系化合物および医薬品におけるそれらの使用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105899508A (zh) * 2014-01-30 2016-08-24 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的新型二氢喹嗪酮类化合物
WO2017016960A1 (en) * 2015-07-24 2017-02-02 F. Hoffmann-La Roche Ag Process for the preparation of (6s)-6-alkyl-10-alkoxy-9-(substituted alkoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid analogues
WO2018047109A1 (en) * 2016-09-09 2018-03-15 Novartis Ag Polycyclic pyridone compounds as antivirals

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR78491B (enExample) 1982-03-24 1984-09-27 Nat Res Dev
JPS60197684A (ja) 1984-03-21 1985-10-07 Dainippon Pharmaceut Co Ltd ベンゾ〔ａ〕キノリジン誘導体およびその塩
ITFI970193A1 (it) 1997-08-01 1999-02-01 Applied Research Systems Uso di derivati benzo(c) chinolizinici come regolatori della crescita delle piante e composizioni ad uso agricolo che contengono tali
TWI232863B (en) 2001-06-11 2005-05-21 Akzo Nobel Nv Benzoxazepine derivatives
US8063037B2 (en) 2007-05-07 2011-11-22 N. V. Organon Progesterone receptor modulators
US8835461B2 (en) * 2009-03-26 2014-09-16 Shionogi & Co., Ltd. Substituted 3-hydroxy-4-pyridone derivative
CN106459032B (zh) 2014-05-13 2019-04-05 豪夫迈·罗氏有限公司 治疗和预防乙型肝炎病毒感染的新的二氢喹嗪酮类
US10415037B2 (en) 2014-10-02 2019-09-17 Arbutus Biopharma Corporation Compositions and methods for silencing hepatitis B virus gene expression
US9637485B2 (en) 2014-11-03 2017-05-02 Hoffmann-La Roche Inc. 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
EP3325477B1 (en) 2015-07-21 2019-05-01 H. Hoffnabb-La Roche Ag Novel tricyclic 4-pyridone-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
CN109071447B (zh) 2016-02-19 2022-04-22 诺华股份有限公司 四环吡啶酮化合物作为抗病毒剂
WO2017216685A1 (en) 2016-06-16 2017-12-21 Novartis Ag Pentacyclic pyridone compounds as antivirals
WO2017216686A1 (en) 2016-06-16 2017-12-21 Novartis Ag 8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
WO2018019297A1 (zh) 2016-07-29 2018-02-01 银杏树药业(苏州)有限公司 异喹啉酮类化合物及其制备抗病毒药物的应用
CA3031063A1 (en) 2016-07-29 2018-02-01 Newave Pharmaceutical Inc. Benzo-quinolizin-2oxo carboxylic acid derivatives for the treatment of hbv infection
CN107759585A (zh) 2016-07-29 2018-03-06 银杏树药业(苏州)有限公司 一种异喹啉类化合物及其药用组合物和作为抗病毒药物的应用
JP7113009B2 (ja) 2016-11-07 2022-08-04 アービュタス バイオファーマ コーポレイション 置換ピリジノン含有三環式化合物およびそれを使用する方法
CN106810548B (zh) 2017-01-13 2019-02-15 苏州爱科百发生物医药技术有限公司 一种二氢异喹啉类化合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105899508A (zh) * 2014-01-30 2016-08-24 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的新型二氢喹嗪酮类化合物
WO2017016960A1 (en) * 2015-07-24 2017-02-02 F. Hoffmann-La Roche Ag Process for the preparation of (6s)-6-alkyl-10-alkoxy-9-(substituted alkoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid analogues
WO2018047109A1 (en) * 2016-09-09 2018-03-15 Novartis Ag Polycyclic pyridone compounds as antivirals

Also Published As

Publication number Publication date
WO2019200109A1 (en) 2019-10-17
US20210032246A1 (en) 2021-02-04
EP3773584A1 (en) 2021-02-17
EP3773584A4 (en) 2022-01-05
TW202010499A (zh) 2020-03-16
US11505551B2 (en) 2022-11-22
AU2019252441A1 (en) 2020-10-22
JP2021521154A (ja) 2021-08-26
KR20200142529A (ko) 2020-12-22
CA3096687A1 (en) 2019-10-17

Similar Documents

Publication Publication Date Title
JP7279057B6 (ja) Ｐｄ１／ｐｄ－ｌ１活性化の阻害剤としてのピリミジン誘導体
CN108055842B (zh) 亚磺酰基苯基或磺亚胺酰基苯基苯并氮杂䓬
JP7398448B2 (ja) ヒト免疫不全ウイルス複製の阻害剤
JP5227304B2 (ja) 新規なヒドロキサム酸誘導体
KR20230019101A (ko) 벤조티아졸릴 비아릴 화합물, 제조 방법 및 용도
JP2022532340A (ja) α－１抗トリプシンモジュレーターとしての縮合三環系ピロール
CN107759602B (zh) 含有共轭联烯结构的化合物、其药物组合物和用途
KR20160127761A (ko) C형 간염 바이러스 억제제 및 약품 제조에서의 이의 용도
RS52407B (sr) Inhibitori virusa hepatitis c
WO2013007106A1 (zh) 作为丙型肝炎病毒抑制剂的螺环化合物
WO2010110231A1 (ja) 置換された３－ヒドロキシ－４－ピリドン誘導体
WO2023125825A1 (en) Anticoronviral compounds and compositions and uses thereof
US10597422B2 (en) Process for making chloro-substituted nucleoside phosphoramidate compounds
WO2021064677A1 (en) Inhibitors of human immunodeficiency virus replication
CN112574269A (zh) 嘌呤核苷类化合物及其用途
CN116406362A (zh) 用于治疗和预防乙型肝炎病毒感染的螺[3.3]庚烷衍生物
US11505551B2 (en) Methods for preparing substituted pyridinone-containing tricyclic compounds
US10251903B2 (en) Process for making nucleoside phosphoramidate compounds
CN113038990A (zh) 新的氨基-嘧啶酮基-哌啶基衍生物、其制备方法以及含有它们的药物组合物
JP2007530516A (ja) 抗ウイルス剤として有用な４−カルボキシピラゾール誘導体
JP2011168586A (ja) アリール基を有する複素環化合物
JP2009073743A (ja) 新規な縮合環式ピリミジン化合物又はその塩、及びその医薬組成物
CN115151537A (zh) 制备杂环胺衍生物的方法
RU2812128C2 (ru) Ингибиторы репликации вируса иммунодефицита человека
HK40067636A (en) Substituted 3,4-dihydroquinazoline for the treatment and prophylaxis of hepatitis b virus infection

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210525

WD01 Invention patent application deemed withdrawn after publication